Valuation: Emergent BioSolutions Inc.

Market Cap 319M 285M 263M 239M 447M 30.32B 454M 3.17B 1.25B 15.87B 1.2B 1.17B 50.09B P/E 2026 *
-1.34x
P/E 2027 * 87.3x
Enterprise Value 690M 616M 568M 516M 966M 65.46B 981M 6.84B 2.71B 34.26B 2.59B 2.53B 108B EV / Sales 2026 *
1.05x
EV / Sales 2027 * 0.89x
Free-Float
43.4%
Yield 2026 *
-
Yield 2027 * -
1 week-13.23%
Current month-5.61%
1 month-7.84%
3 months-17.81%
6 months-24.85%
Current year-49.60%
1 week 6.01
Extreme 6.01
6.58
1 month 6.01
Extreme 6.01
7.65
Current year 4.36
Extreme 4.36
14.06
1 year 4.36
Extreme 4.36
14.06
3 years 1.42
Extreme 1.42
15.1
5 years 1.42
Extreme 1.42
52.76
10 years 1.42
Extreme 1.42
137.61
Manager TitleAgeSince
Chief Executive Officer 70 20/02/2024
Director of Finance/CFO 62 25/03/2018
Compliance Officer 55 29/02/2020
Director TitleAgeSince
Chairman 82 31/03/2022
Director/Board Member 70 31/12/2004
Director/Board Member 77 30/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Sell

Director

-17,800 0.0347%
01/10/26 Sell

Executive/Senior Manager

-3,000 0.0059%
05/08/26 Other

Executive/Senior Manager

455,311 0.8824%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-13.23%-33.93%+181.90% 319M
-2.54%+1.75%+56.75%+117.82% 1,165B
-1.42%+4.16%+36.73%+72.42% 645B
+0.16%+0.79%+24.91%+95.34% 504B
-0.31%+2.95%+39.36%+63.56% 380B
-1.34%+0.06%+65.81%+41.49% 363B
-0.68%+1.67%+22.07%+50.94% 297B
-1.20%+0.99%+2.26%+22.95% 269B
-1.79%+1.20%+48.41%+57.55% 237B
-0.73%-0.85%+28.47%+100.57% 195B
Average -0.76%+0.97%+29.08%+80.45% 405.58B
Weighted average by Cap. -0.60%+3.17%+40.78%+80.34%

Financials

2026 *2027 *
Net sales 657M 587M 542M 491M 920M 62.38B 934M 6.52B 2.58B 32.65B 2.47B 2.41B 103B 703M 628M 580M 526M 985M 66.77B 1B 6.98B 2.76B 34.95B 2.64B 2.58B 110B
Net income -239M -213M -197M -179M -335M -22.7B -340M -2.37B -939M -11.88B -897M -878M -37.5B 3.83M 3.42M 3.15M 2.86M 5.36M 363M 5.44M 37.97M 15.02M 190M 14.36M 14.05M 600M
Net Debt 370M 330M 305M 277M 518M 35.14B 526M 3.67B 1.45B 18.39B 1.39B 1.36B 58.05B 309M 276M 255M 231M 432M 29.32B 439M 3.06B 1.21B 15.35B 1.16B 1.13B 48.43B
Projected Income Statement - Annual - Emergent BioSolutions Inc.
Logo Emergent BioSolutions Inc.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Employees
900
Date Price Change Volume
23/10/26 US$6.230 0.00% 727,320
22/10/26 US$6.230 +0.48% 838,558
21/10/26 US$6.200 -1.43% 851,823
20/10/26 US$6.290 -1.10% 1,313,848
19/10/26 US$6.360 -0.31% 817,334
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Emergent BioSolutions Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.230USD
Average target price
11.00USD
Spread / Average Target
+76.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Emergent BioSolutions Inc.